Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes

Abstract: The pineal product melatonin has remarkable antioxidant properties. It is secreted during darkness and plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation and vasomotor responses. It scavenges hydroxyl, carbonate and various organic radicals as well as a number of reactive nitrogen species. Melatonin also enhances the antioxidant potential of the cell by stimulating the synthesis of antioxidant enzymes including superoxide dismutase, glutathione peroxidase and glutathione reductase, and by augmenting glutathione levels. Melatonin preserves mitochondrial homeostasis, reduces free radical generation and protects mitochondrial ATP synthesis by stimulating Complex I and IV activities. The decline in melatonin production in aged individuals has been suggested as one of the primary contributing factors for the development of age-associated neurodegenerative diseases. The efficacy of melatonin in preventing oxidative damage in either cultured neuronal cells or in the brains of animals treated with various neurotoxic agents, suggests that melatonin has a potential therapeutic value as a neuroprotective drug in treatment of Alzheimer´s disease (AD), Parkinson´s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington´s disease (HD), stroke and brain trauma. Therapeutic trials with melatonin indicate that it has a potential therapeutic value as a neuroprotective drug in treatment of AD, ALS and HD. In the case of other neurological conditions, like PD, the evidence is less compelling. Melatonin’s efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke. Clinical trials employing melatonin doses in the range of 50–100 mg/day are warranted before its relative merits as a neuroprotective agent is definitively established.

Saved in:
Bibliographic Details
Main Authors: Pandi Perumal, Seithikurippu R., BaHammam, Ahmed S., Spence, David Warren, Brown, Gregory M., Bharti, Vijay K., Kaur, Charanjit, Hardeland, Rüdiger, Cardinali, Daniel Pedro
Format: Artículo biblioteca
Language:eng
eng
Published: Springer 2012
Subjects:MELATONINA, RADICALES LIBRES, STRESS, ENVEJECIMIENTO, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE HUNTINGTON,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/1620
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-1620
record_format koha
spelling oai:ucacris:123456789-16202020-08-19T22:32:15Z Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes Pandi Perumal, Seithikurippu R. BaHammam, Ahmed S. Spence, David Warren Brown, Gregory M. Bharti, Vijay K. Kaur, Charanjit Hardeland, Rüdiger Cardinali, Daniel Pedro MELATONINA RADICALES LIBRES STRESS ENVEJECIMIENTO ENFERMEDAD DE PARKINSON ENFERMEDAD DE ALZHEIMER ENFERMEDAD DE HUNTINGTON Abstract: The pineal product melatonin has remarkable antioxidant properties. It is secreted during darkness and plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation and vasomotor responses. It scavenges hydroxyl, carbonate and various organic radicals as well as a number of reactive nitrogen species. Melatonin also enhances the antioxidant potential of the cell by stimulating the synthesis of antioxidant enzymes including superoxide dismutase, glutathione peroxidase and glutathione reductase, and by augmenting glutathione levels. Melatonin preserves mitochondrial homeostasis, reduces free radical generation and protects mitochondrial ATP synthesis by stimulating Complex I and IV activities. The decline in melatonin production in aged individuals has been suggested as one of the primary contributing factors for the development of age-associated neurodegenerative diseases. The efficacy of melatonin in preventing oxidative damage in either cultured neuronal cells or in the brains of animals treated with various neurotoxic agents, suggests that melatonin has a potential therapeutic value as a neuroprotective drug in treatment of Alzheimer´s disease (AD), Parkinson´s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington´s disease (HD), stroke and brain trauma. Therapeutic trials with melatonin indicate that it has a potential therapeutic value as a neuroprotective drug in treatment of AD, ALS and HD. In the case of other neurological conditions, like PD, the evidence is less compelling. Melatonin’s efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke. Clinical trials employing melatonin doses in the range of 50–100 mg/day are warranted before its relative merits as a neuroprotective agent is definitively established. 2019-05-02T14:01:09Z 2019-05-02T14:01:09Z 2012 Artículo Pandi-Perumal, S. R., et al. Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes [en línea]. Preprint del documento publicado en Neurotoxicity Research. 2012, 23. doi: 10.1007/s12640-012-9337-4. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1620 1029-8428 (impreso) 1476-3524 (online) https://repositorio.uca.edu.ar/handle/123456789/1620 10.1007/s12640-012-9337-4 eng eng Acceso Abierto https://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Springer Neurotoxicity Research. 2013, 23
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
eng
topic MELATONINA
RADICALES LIBRES
STRESS
ENVEJECIMIENTO
ENFERMEDAD DE PARKINSON
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE HUNTINGTON
MELATONINA
RADICALES LIBRES
STRESS
ENVEJECIMIENTO
ENFERMEDAD DE PARKINSON
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE HUNTINGTON
spellingShingle MELATONINA
RADICALES LIBRES
STRESS
ENVEJECIMIENTO
ENFERMEDAD DE PARKINSON
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE HUNTINGTON
MELATONINA
RADICALES LIBRES
STRESS
ENVEJECIMIENTO
ENFERMEDAD DE PARKINSON
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE HUNTINGTON
Pandi Perumal, Seithikurippu R.
BaHammam, Ahmed S.
Spence, David Warren
Brown, Gregory M.
Bharti, Vijay K.
Kaur, Charanjit
Hardeland, Rüdiger
Cardinali, Daniel Pedro
Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
description Abstract: The pineal product melatonin has remarkable antioxidant properties. It is secreted during darkness and plays a key role in various physiological responses including regulation of circadian rhythms, sleep homeostasis, retinal neuromodulation and vasomotor responses. It scavenges hydroxyl, carbonate and various organic radicals as well as a number of reactive nitrogen species. Melatonin also enhances the antioxidant potential of the cell by stimulating the synthesis of antioxidant enzymes including superoxide dismutase, glutathione peroxidase and glutathione reductase, and by augmenting glutathione levels. Melatonin preserves mitochondrial homeostasis, reduces free radical generation and protects mitochondrial ATP synthesis by stimulating Complex I and IV activities. The decline in melatonin production in aged individuals has been suggested as one of the primary contributing factors for the development of age-associated neurodegenerative diseases. The efficacy of melatonin in preventing oxidative damage in either cultured neuronal cells or in the brains of animals treated with various neurotoxic agents, suggests that melatonin has a potential therapeutic value as a neuroprotective drug in treatment of Alzheimer´s disease (AD), Parkinson´s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington´s disease (HD), stroke and brain trauma. Therapeutic trials with melatonin indicate that it has a potential therapeutic value as a neuroprotective drug in treatment of AD, ALS and HD. In the case of other neurological conditions, like PD, the evidence is less compelling. Melatonin’s efficacy in combating free radical damage in the brain suggests that it can be a valuable therapeutic agent in the treatment of cerebral edema following traumatic brain injury or stroke. Clinical trials employing melatonin doses in the range of 50–100 mg/day are warranted before its relative merits as a neuroprotective agent is definitively established.
format Artículo
topic_facet MELATONINA
RADICALES LIBRES
STRESS
ENVEJECIMIENTO
ENFERMEDAD DE PARKINSON
ENFERMEDAD DE ALZHEIMER
ENFERMEDAD DE HUNTINGTON
author Pandi Perumal, Seithikurippu R.
BaHammam, Ahmed S.
Spence, David Warren
Brown, Gregory M.
Bharti, Vijay K.
Kaur, Charanjit
Hardeland, Rüdiger
Cardinali, Daniel Pedro
author_facet Pandi Perumal, Seithikurippu R.
BaHammam, Ahmed S.
Spence, David Warren
Brown, Gregory M.
Bharti, Vijay K.
Kaur, Charanjit
Hardeland, Rüdiger
Cardinali, Daniel Pedro
author_sort Pandi Perumal, Seithikurippu R.
title Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
title_short Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
title_full Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
title_fullStr Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
title_full_unstemmed Melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
title_sort melatonin antioxidative defense : therapeutical implications for aging and neurodegenerative processes
publisher Springer
publishDate 2012
url https://repositorio.uca.edu.ar/handle/123456789/1620
work_keys_str_mv AT pandiperumalseithikurippur melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT bahammamahmeds melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT spencedavidwarren melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT browngregorym melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT bhartivijayk melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT kaurcharanjit melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT hardelandrudiger melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
AT cardinalidanielpedro melatoninantioxidativedefensetherapeuticalimplicationsforagingandneurodegenerativeprocesses
_version_ 1756275062006087680